Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $38 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Abeona Therapeutics (NASDAQ:ABEO) and maintained a $38 price target.
August 24, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Abeona Therapeutics and maintained a $38 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Abeona Therapeutics. The maintained price target of $38 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100